$VREX

Compared to Estimates, VAREX IMAGING (VREX) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for VAREX IMAGING (VREX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 18, 2025, 10:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 19, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Compared to Estimates, VAREX IMAGING (VREX) Q4 Earnings: A Look at Key Metrics — source image
Decision brief

The 30-second read

$VREXNeutralMed
01

Why it matters

The earnings report suggests stability but lacks significant surprises, leading to limited immediate trading action. Investors should monitor technical indicators and broader sector trends for potential opportunities.

02

Market read

The news has moderate relevance for traders focusing on the medical imaging sector and short-term earnings impacts.

03

What to watch

Potential upcoming product launches or regulatory changes could influence future performance beyond current earnings analysis.

Timing: short-term (next few trading sessions)

Background

VAREX IMAGING reported its Q4 2025 earnings, with key metrics compared to Wall Street estimates and previous year figures, providing insights into its financial health.

Company-level read

Ticker impact

$VREXNeutralMedium confidence
Context

The article discusses VAREX IMAGING's Q4 2025 earnings and compares key metrics to estimates and previous year values, providing insights into its financial performance.

Expected impact

Minimal immediate price movement expected; potential for slight volatility around earnings release.

Evidence & confidence

The mixed earnings data and lack of significant surprises suggest limited short-term price impact, but investor sentiment could cause minor fluctuations.

Market effects

The medical imaging sector may experience slight volatility; sector peers' performance could influence VREX's stock movement.

Limited regional impact; primarily affects investors focused on the company's domestic and international markets.

Low; VAREX IMAGING is a niche player with limited global market influence.

Counterpoint

If upcoming industry data or macroeconomic factors turn positive, VREX could outperform expectations despite neutral earnings.

Key entities

  • VAREX IMAGING

    A provider of medical imaging components and solutions.

Related articles

$METAMed

Futures Erase Overnight Gains As Oil Hits One-Week High, Yen Slides

US equity futures largely gave back overnight gains after oil hit a one-week high and the yen weakened. Traders await US CPI and PPI, with rate-hike bets cooling after Friday’s jobs report. JPMorgan raised its S&P 500 year-end target to 8000. Corporate movers include AAON (+8%), ABCL (+22%), HZO halted on a $53 buyout, and VREX surging on Teledyne’s $18.90 offer.

$TDYHighAI 9/10

Teledyne to acquire Varex Imaging in $1.1 billion deal

Teledyne Technologies agreed to acquire Varex Imaging in an all-cash deal valued at about $1.1 billion, paying $18.90 per share, according to the companies. The transaction would bring Teledyne’s sensing-systems business together with Varex’s medical imaging components.

$VREXHighAI 10/10

Why is Varex Imaging stock rocketing today?

Investing.com reports Varex Imaging (VREX) shares rose about 49.5% in pre-open to $18.55 after Teledyne Technologies announced an agreement to buy all outstanding Varex shares for $18.90 per share in cash, valuing the deal at about $1.1 billion including equity awards and net debt. Boards approved; close expected early 2027 pending approvals.

$XOMMed

ExxonMobil in Mozambique awards McDermott LoI for Rovuma LNG project

ExxonMobil Moçambique Limitada, for the Area 4 partners, awarded McDermott Energy Solutions a letter of intent for limited engineering and procurement supporting Rovuma LNG Phase 1 midstream development. The Area 4 partners target a final investment decision in 2026. Rovuma LNG is expected to produce 18.6 million tonnes per year, start in 2031, and ExxonMobil says it is its largest single investment.